Home>Topics>Finance>Bill Ackman

Bill Ackman

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. Ackman supports Allergan's $66 billion sale to Actavis

    Headlines

    Tue, 18 Nov 2014

    (Reuters) - Activist investor William Ackman said on Tuesday he supports the $66 billion deal in which Actavis PLC will buy Allergan Inc and will withdraw his request for an Allergan special shareholder meeting.

  2. UPDATE 1-Ackman supports Allergan's $66 billion sale to Actavis

    Headlines

    Tue, 18 Nov 2014

    Nov 18 (Reuters) - Activist investor William Ackman said on Tuesday he supports the $66 billion deal in which Actavis PLC will buy Allergan Inc and will withdraw his request for an Allergan special...

  3. Ackman says supports Allergan's $66 billion sale to Actavis -CNBC

    Headlines

    Tue, 18 Nov 2014

    Nov 18 (Reuters) - Activist investor William Ackman is supporting the $66 billion deal in which Actavis PLC will buy Allergan Inc and plans to withdraw from an Allergan special shareholder meeting he had planned, CNBC television reported on Tuesday.

  4. Allergan agrees to $66 billion Actavis offer; Valeant walks

    Headlines

    Mon, 17 Nov 2014

    (Reuters) - Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc, ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc.

  5. UPDATE 4-Allergan agrees to $66 bln Actavis offer; Valeant walks

    Headlines

    Mon, 17 Nov 2014

    Nov 17 (Reuters) - Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc , ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc.

  6. Allergan agrees to Actavis deal for $66 billion

    Headlines

    Mon, 17 Nov 2014

    Nov 17 (Reuters) - Allergan Inc agreed to be bought by Actavis Plc for $66 billion, more than $12 billion above the current value of a hostile bid by activist investor William Ackman and Valeant Pharmaceuticals International Inc .

  7. Actavis Beats Out Valeant’s Hostile Bid for Wide-Moat Allergan

    Commentary

    Mon, 17 Nov 2014

    for Allergan. We don’t anticipate Actavis’ $219 offer will spur a bidding war with Valeant and its partnership with Bill Ackman ’s Pershing Square, which was previously pursuing a hostile takeover with a last official bid near $180. Although we

  8. Allergan near buyout of up to $65 billion to escape Valeant, Ackman: source

    Headlines

    Sun, 16 Nov 2014

    up to $65.5 billion by Actavis Plc, one that could end months of pursuit by Canada’s Valeant Pharmaceuticals and William Ackman 's hedge fund, Pershing Square Capital Management, according to a person familiar with the matter.

  9. Zoetis adopts poison pill after Ackman picks up stake

    Headlines

    Fri, 14 Nov 2014

    Nov 14 (Reuters) - Zoetis Inc adopted a poison pill, three days after activist investor William Ackman 's Pershing Square Capital Holdings revealed a stake in the animal health company.

  10. Allergan amends shareholder meeting bylaws ahead of Dec. 18 meet

    Headlines

    Wed, 12 Nov 2014

    Nov 12 (Reuters) - Allergan Inc changed its bylaws associated with calling a special shareholder meeting, about a month before such a meeting where William Ackman , the Botox maker's biggest...

« Prev12345Next »
Content Partners